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rate into neovascularization of the injured tissue. Therefore, this study was designed to 
examine if CD34+ MNCs delivered intracoronary in Infarcted hearts will incorporate in 
neovessels and enhance capillary density within the injured myocardium. Myocardial inf- 
arction was created in inbred Brown Norway (BN) rats. CD34+ MNCs cells were isolated 
from donor BN rats using magnetic beads conjugated to anti-CD34 antibody and the cells 
ware labeled with CFDA SE labeling kit (fluorescence dye). Immediately after infarction, 
1x1@ of the labeled CD34+ MNCs were delivered intracoronary into the infarcted myo- 
cardium. Four weeks after cell delivery, myocardium was sectioned, stained with factor 
VIII. and examined using fluorescence microscopy. Our data show that bone rnarrow- 
derived CD34+ MNCs incorporated into neovessels within the injured myocardium. It also 
ted to increase in capillary density by 18% compared to untreated infarcted rats. In addi- 
tion, a small number of the injected CD34+ MNCs (~0.01%) differentiated into cardiomy- 
ocytes and incorporated within the survived myocardium. Thus, intracoronary delivery of 
bone marrow CD34+ cells may be viable therapeutic option to enhance neovasculariza- 
tion in the injured myocardium after Ml. 
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878-6 Platelet Collagen Receptor Glycoprotein VI as a Novel 
Risk Factor for Myocardial Infarction 
Frederick F. Samaha, Michael Varello, Mark L. Kahn, Philadelphia VA Medical Center, 
Philadelphia, PA, University of Pennsylvania, Philadelphia, PA 
Introduction: Following plaque rupture, the response of circulating platelets determines 
whether thrombotic occlusion with myocardial infarction (Ml) or plaque stabilization 
occur. The first activating signal to which platelets are exposed following vessel injury is 
collagen. The expression level of platelet collagen receptor glycoprotein (GP) VI is pro- 
portional to the strength of collagen signaling responses in cell lines, and polymorphisms 
associated with elevated platelet collagen receptor a2bl expression have been associ- 
ated with an increased risk of stroke. We used a novel anti-GPVI m~n~clonal antibody, 
and an antia2bl antibody to assess whether collagen receptor expression levels are risk 
factors for MI. 
Methods: We used flow cytometry with FITC-conjugated monoclonal antibody to assess 
receptor expression level in 44 subjects with and 56 subjects without a history of Ml. 
Results: GPVI receptor density was significantly higher in subjects with history of Ml 
(2891 +/- 1482 molecules of equivalent fluorescence) (MEF) versus those with no history 
of Ml (2348 +/- 1231 MEF) (p=O.O48), though less so after correction for baseline tradi- 
tional Ml risk factors (p=O.O57). However, subjects with Ml prior to age 50 had incremen- 
tally higher GPVI levels (3260 +/- 1740 MEF) compared to those with no history of Ml 
(p=O.O26), independently of baseline traditional risk factors (p=O.O43). There was no 
association between a2bl receptor density and Ml (p=O.21) or MI under age 50 (p=O.27). 
Conclusion: GPVI expression level is a novel independent risk factor for myocardial inf- 
arction, especially in younger patients. These results suggest that elevated GPVI levels 
may result in more rapid and complete platelet activation following plaque rupture, 
increasing the likelihood of thrombotic occlusion and myocardial infarction. 
ORAL CONTRIBUTIONS 
881 FO Featured Oral Session...Novel Therapies 
as Adjuncts for Reperfusion 
Wednesday, April 02, ?003, IO:30 a.m.-Noon 
McCormick Place, Room S105 
IO:45 a.m. 
881 FO-2 Clinical Evidence for Benefit of lntracoronary 
Progenitor Cell Therapy on Post-Infarction Remodeling: 
Results of the TOPCARE-AMI Trial 
Volker Schachinqer, Birgit Assmus, Ralf Lehmann, Claudius Teupe. Martina Britten, 
Natascha Doebert, Hans Martin. Stefanie Dimmeler, Andreas M. Zeiher, J. W. Goethe 
University, Frankfurt, Germany 
Background: Experimentally, blood or bone-marrow derived prognitor cells were shown 
to contribute to regeneration and neovascularization of ischemic tissue. In this pilot 
study, we tested the safety and feasibility of autologous progenitor cell transplantation 
after acute myocardial infarction (AMI). 
Methods: We randomly allocated 20 patients with repelfused AMI to receive intracoro- 
nary infusion of either bone marrow-derived (w9) or circulationg blood-derived progeni- 
tor cells (n=l I) into the infarct artery 4.3&l .5 days after AMI. Left ventricular angiography 
(LVA), coronary flow reserve (i.c. adenosine), echocardiography and FDG-PET were 
performed at the time of progenitor cell infusion and after 4 months. Results: Transplan- 
tation of progenitor cells was associated with a significant increase in global left ventricu- 
lar ejection fraction by LVA from 52t9.6 to 60+8.6 % (p=O.O03) and a reduction of 
endsystolic left ventricular volumes (56t20 to 42*14 ml; p=O.Ol). Echocardiography 
revealed a profound enhancement of regional contractile function in the infarct zone 
(decrease in wall motion score index from 1.4kO.2 to 1.2*0.2; p-zO.001) accompanied by 
a significant increase in myocardial viability detected by quantitative FDG-PET analysis 
(54il3 to 63+1 I; pcO.01). At baseline, CFR was significantly impaired in the infarct 
artery compared to the reference vessel (2.4iO.55 vs. 3.450.80, p<O.Ol). After 4 months, 
CFR was significantly improved in the infarct artery and did no longer differ from CFR in 
the reference vessel (4.2~1.2 vs. 4.5kO.8, p=n.s.). For all parameters assessed, there 
were no differences between patients treated with bone marrow-derived compared to cir- 
culating blood-derived cells. No signs of an inflammatory response or malignant arrhyth- 
mias were observed. Conclusions: In patients with acute myocardral infarction 
undergoing acute revascularization. intracoronary infusion of autologous progenitor cells 
appears to be feasable and safe. Furthermore, compared to historical data, this pilot 
study suggests a beneficial effect of progenitor cells on coronary blood flow regulation 
and post infarction remodeling processes. 
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881 FO-3 Protection Against Reperfusion Injury With ITF-1697 in 
Acute Myocardial Infarction: The PARI-MI Trial 
Maurfts T. Dirksen, Arnoud W. van ‘t Hof. G. Guagliumi. H. R. Michels, M. L. Sirnoons, L. 
Tavazzi, G. J. Laarman. for the PARI-MI Investigators, Onze Lieve Vrouwe Gasthuis. 
Amsterdam, The Netherlands, Erasmus Medical Centre, Rotterdam, The Netherlands 
Background: ITF-1697 is a C-reactive protein-derived tetrapeptide that increases myo- 
cardial perfusion and reduces infarct size in various experimental animal models of 
ischemia and ischemia-reperfusion. ITF-1697 is thought to reduce reperfusion injury by 
preservation of the integrity of microcirculation and inhibition of polymorphonuclear neu- 
trophil and platelet adhesion to the endothelium. The study was performed to assess 
safety, efficacy and clinical outcome of prolonged i.v. infusion of ITF-1697 in 4 dosages 
(0.1,0.5, 1 .O and 2.0 “gikglmin), in patients wth an acute myocardial infarction (AMI) eli- 
gible for primary percutaneous angioplasty (PCI). 
Methods The design of the study was randomized, double blind, multicentre, placebo- 
controlled and dose finding. Patients with AMI were enrolled within 12 hours after onset 
of symptoms, with ST-segment deviation more than 0.2 mV in two or more contiguous 
leads and sum of ST elevation more than IO mm. I.v. infusion was started before proce- 
dure up to 24 hours. Safety was evaluated by incidence of death and serious adverse 
events (SAEs). Efficacy was measured by improved perfusion (TIMI flow, TIMI frame 
count, blush grade, ST-segment resolution) and reduced myocardial damage (enzy- 
matic). Clinical outcome was assessed by incidence of death, recurrent AMI, recurrent 
ischemia and SAEs. 
Results: 402 patients were enrolled. After interim analysis the study was continued with 
0.1 and 1.0 ITF-1697 @kgfmin. Interim and final analysis did not raise any safety con- 
cerns. Post-procedure perfusion was similar for placebo, 0.1 and 1.0. TIMI flow grade.3 
was seen in 82.2%, 84.4% (ns) and 87.5% (ns) respectively, blush grade 3 in 32.5%, 
16.7% (ns) and 18.5% (ns) respectively. No differences were shown in the corrected 
TIMI frame count. ST-segment resolution 1 and 3 hours after PCI was equal. Enzymatic 
infarct size was not different between the three groups. At discharge and after 30 days 
follow-up no significant differences between placebo and one of the dosages could be 
detected in clinical outcome. 
Conclusion: Although well tolerated, ITF-1697 failed to show improvement of perfusion 
or reduction of myocardial damage after primary PCI in patients with AMI. 
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881 FO-4 Efficacy of a Novel P-Selectin Antagonist, rPSGL-lg for 
Reperfusion Therapy in Acute Myocardial Infarction: 
The RAPSODY Trial 
Jean-Francois Tanauay, Mitchell W. Krucoff, Raymond J. Gibbons, Eduardo Chavez, 
Alvaro Sosa Liprandi, Victor Molina-Viamonte, Philip E. Aylward, Jose Luis Lopez- 
Sendon, D. Scott Holloway, Kathy Shields, Jenny S. Yu, Evan Loh, Kenneth W. Baran. 
Vasanth K. Bethala. Alec Vahanian, Harvey D. White, for the RAPSODY Investigators, 
Montreal Heart Institute, Montreal, Canada, Wyeth Research, Collegeville, PA 
Background: Platelet-leukocyte interactions, mediated by P-selectin, have been impli- 
cated in thrombosis. A recombinant antagonist (rPSGL-lg) in conjunction with throm- 
bolytic therapy (tPA) has been demonstrated in pre-clinical studies to accelerate 
thrombolysis, reduce reperfusion injury. and reduce reocclusion. This multicenter. ran- 
domized trial, dose-rangrng study was performed using rPSGL-Ig in combination with tPA 
in patients with AMI to determine if P-selectin antagonism will improve ST segment reso- 
lution and infarct size. 
Methods: 598 patients who presented with ST elevation and chest pain ~6 hours, and 
who were eligible for thrombolytic therapy were included. All patients received tPA. Three 
(3) doses of rPSGL-Ig were compared with placebo. Continuous IPlead ST-monitoring 
was performed for the first 24 hours. Infarct srze and ejection fraction were determined by 
sestamibi-SPECT on day 7 and MUGA on day 30. Clinical outcome was monitored for 6 
months. 
Results: No differences were observed in baseline charactenstics (age, sex, diabetes, 
Ml location, time to tPA). 
rPSGL-Ig Dose 0 5 25 75 p-Value’ 
mg mg mg mg 
N 144 148 151 155 
Time to ST Resolution (hr)#@ 2.0 2.0 2.2 2.5 0.006 
InfarctSizeanterior (%LV)# 26 35 37 26 NS 
Infarct Size other (%LV)# 13 9 16 13 NS 
Ejection Fraction (%)#a 52 50 51 51 NS 
Death/Ml Day 30 (%) 7 2 5 7 NS 
Death/MI Month 6 (%) 8 11 10 IO NS 
Stroke (%) 3.5 2.0 2.0 1.3 NS 
